NasdaqGS:SNDXBiotechs
Did New Revuforj Post‑Transplant Data at ASCO 2026 Just Shift Syndax Pharmaceuticals' (SNDX) Investment Narrative?
Syndax Pharmaceuticals recently announced that four Revuforj (revumenib) abstracts were accepted for presentation at the ASCO 2026 meeting, including new post‑transplant maintenance and pharmacokinetic data in acute leukemia.
A particularly important element is the oral presentation comparing survival and relapse outcomes for revumenib-treated post‑transplant patients against a historical cohort, offering an early real‑world benchmark for the drug’s clinical impact.
We’ll now examine how the...